0 Évaluations
ID

17507

Description

Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201; ODM derived from: https://clinicaltrials.gov/show/NCT00362700

Lien

https://clinicaltrials.gov/show/NCT00362700

Mots-clés

Versions (1)
  1. 19/09/2016 19/09/2016 -
Téléchargé le

19 septembre 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

  • Plus récent
  • Plus ancien
  • Favori
  • Plus récent
    • Plus récent
    • Plus ancien
    • Favori

    Aucun commentaire

    Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

    Eligibility Hepatitis B NCT00362700

    Anglais

    Eligibility Hepatitis B NCT00362700

    1 Formulaires  
    Inclusion Criteria
    Description

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    1. patients who received clevudine in l-fmau-201 clinical trial (phase iib)
    Description

    Clevudine | l-fmau Clinical Trial

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0045212
    UMLS CUI [2,1]
    C0045212
    UMLS CUI [2,2]
    C0008976
    2. female of childbearing potential must have a negative serum ( b-hcg) pregnancy test within 14 days of starting therapy.
    Description

    Childbearing Potential Serum pregnancy test negative | Childbearing Potential Serum Beta-HCG Test Negative

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C3831118
    UMLS CUI [1,2]
    C0430061
    UMLS CUI [2,1]
    C3831118
    UMLS CUI [2,2]
    C1255526
    UMLS CUI [2,3]
    C1513916
    3. patient is able to give written informed consent prior to study start and to comply with the study requirements.
    Description

    Informed Consent | Protocol Compliance

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0021430
    UMLS CUI [2]
    C0525058
    4. patients who met the following criteria after completion of the week 48 visit were to have additional follow-up visits at weeks 54 and 60: 1) had received no additional therapy since completion of 24-week treatment of clevudine and 2)experienced a > 1 log10 decrease from baseline in hbv dna at week 48
    Description

    Patient Visit | Follow-up visit Additional | Additional Therapy | Clevudine | HBV DNA decreased

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1512346
    UMLS CUI [2,1]
    C0589121
    UMLS CUI [2,2]
    C1524062
    UMLS CUI [3]
    C1706712
    UMLS CUI [4]
    C0045212
    UMLS CUI [5]
    C1262160
    Exclusion Criteria
    Description

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    1. hbv dna negative (< 4,700 copies/ml) consistently at the last 2 visit (at least 2 consecutive visits, at one month interval)
    Description

    Hbv DNA Test Negative

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C1256114
    UMLS CUI [1,2]
    C1513916
    2. patient is currently receiving antiviral immunomodulatory or corticosteroid therapy.
    Description

    Antiviral Therapy | Biological Response Modifier Therapy | Steroid therapy

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0280274
    UMLS CUI [2]
    C0005527
    UMLS CUI [3]
    C0149783
    3. patients previously treated with lamivudine, lobucavir, adefovir or any other investigational nucleoside for hbv infection after cessation of treatment in l-fmau-201 study.
    Description

    Lamivudine | lobucavir | adefovir | Nucleoside Investigational | Therapeutic procedure Hepatitis B | Clevudine Clinical Trial Therapeutic procedure Ended

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0209738
    UMLS CUI [2]
    C0286536
    UMLS CUI [3]
    C0050175
    UMLS CUI [4,1]
    C0028621
    UMLS CUI [4,2]
    C1517586
    UMLS CUI [5,1]
    C0087111
    UMLS CUI [5,2]
    C0019163
    UMLS CUI [6,1]
    C0045212
    UMLS CUI [6,2]
    C0008976
    UMLS CUI [6,3]
    C0087111
    UMLS CUI [6,4]
    C1272693
    4. patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
    Description

    Ascites | Bleeding varices | Hepatic Encephalopathy

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0003962
    UMLS CUI [2]
    C0333106
    UMLS CUI [3]
    C0019151
    5. patient is coinfected with hcv, hdv or hiv.
    Description

    HCV coinfection | Coinfection HDV | HIV coinfection

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1698259
    UMLS CUI [2,1]
    C0275524
    UMLS CUI [2,2]
    C0011220
    UMLS CUI [3]
    C4062778
    6. patient with clinical evidence of cirrhosis or hepatocellular carcinoma (®-fetoprotein) evaluation will be based on alpha-fetoprotein primarily. if alpha-fetoprotein level is suggestive of cirrhosis or hepatocellular carcinoma, confirmation will be made with sonography etc.
    Description

    Liver Cirrhosis Evidence Clinical | Liver carcinoma Evidence Clinical | Alpha fetoprotein measurement | Sonography

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0023890
    UMLS CUI [1,2]
    C3887511
    UMLS CUI [1,3]
    C0205210
    UMLS CUI [2,1]
    C2239176
    UMLS CUI [2,2]
    C3887511
    UMLS CUI [2,3]
    C0205210
    UMLS CUI [3]
    C0201539
    UMLS CUI [4]
    C0041618
    7. patient is pregnant or breast-feeding.
    Description

    Pregnancy | Breast Feeding

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0032961
    UMLS CUI [2]
    C0006147
    8. patient is unwilling to use an “effective” method of contraception during the study and for up to 3 months after the use of study drug ceases. for males, condoms should be used. females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal or using at least a medically acceptable barrier method of contraception (i.e., iud, barrier methods with spermicide or abstinence)
    Description

    Contraceptive methods Unwilling | Condoms, Male | Female Sterilization | Hysterectomy | Bilateral tubal ligation | Postmenopausal state | Contraception, Barrier | Intrauterine Devices | Vaginal Spermicides | Sexual Abstinence

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0700589
    UMLS CUI [1,2]
    C0558080
    UMLS CUI [2]
    C0009653
    UMLS CUI [3]
    C0015787
    UMLS CUI [4]
    C0020699
    UMLS CUI [5]
    C0589114
    UMLS CUI [6]
    C0232970
    UMLS CUI [7]
    C0004764
    UMLS CUI [8]
    C0021900
    UMLS CUI [9]
    C0087145
    UMLS CUI [10]
    C0036899
    9. patient has a clinically relevant history of abuse of alcohol or drugs.
    Description

    Substance Use Disorders Relevant Clinical

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0038586
    UMLS CUI [1,2]
    C2347946
    UMLS CUI [1,3]
    C0205210
    10. patient has a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease.
    Description

    Gastrointestinal Diseases Significant | Kidney Diseases | Decompensated liver disease | Bronchopulmonary disease | nervous system disorder | Cardiovascular Diseases | Malignant Neoplasms | Hypersensitivity

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0017178
    UMLS CUI [1,2]
    C0750502
    UMLS CUI [2]
    C0022658
    UMLS CUI [3]
    C4075847
    UMLS CUI [4]
    C1096000
    UMLS CUI [5]
    C0027765
    UMLS CUI [6]
    C0007222
    UMLS CUI [7]
    C0006826
    UMLS CUI [8]
    C0020517
    11. patient has creatinine clearance less than 60ml/min as estimated by the following formula:
    Description

    Estimation of creatinine clearance by Cockcroft-Gault formula

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C2711451
    (140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dl]) [note: multiply estimates by 0.85 for women]
    Description

    Age | Body Weight | Creatinine measurement, serum | Gender

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0001779
    UMLS CUI [2]
    C0005910
    UMLS CUI [3]
    C0201976
    UMLS CUI [4]
    C0079399
    Retour au début de la page

    Similar models

    Eligibility Hepatitis B NCT00362700

    1 Formulaires
    Name
    Type
    Description | Question | Decode (Coded Value)
    Type de données
    Alias
    Item Group
    C1512693 (UMLS CUI)
    Clevudine | l-fmau Clinical Trial
    Item
    1. patients who received clevudine in l-fmau-201 clinical trial (phase iib)
    boolean
    C0045212 (UMLS CUI [1])
    C0045212 (UMLS CUI [2,1])
    C0008976 (UMLS CUI [2,2])
    Childbearing Potential Serum pregnancy test negative | Childbearing Potential Serum Beta-HCG Test Negative
    Item
    2. female of childbearing potential must have a negative serum ( b-hcg) pregnancy test within 14 days of starting therapy.
    boolean
    C3831118 (UMLS CUI [1,1])
    C0430061 (UMLS CUI [1,2])
    C3831118 (UMLS CUI [2,1])
    C1255526 (UMLS CUI [2,2])
    C1513916 (UMLS CUI [2,3])
    Informed Consent | Protocol Compliance
    Item
    3. patient is able to give written informed consent prior to study start and to comply with the study requirements.
    boolean
    C0021430 (UMLS CUI [1])
    C0525058 (UMLS CUI [2])
    Patient Visit | Follow-up visit Additional | Additional Therapy | Clevudine | HBV DNA decreased
    Item
    4. patients who met the following criteria after completion of the week 48 visit were to have additional follow-up visits at weeks 54 and 60: 1) had received no additional therapy since completion of 24-week treatment of clevudine and 2)experienced a > 1 log10 decrease from baseline in hbv dna at week 48
    boolean
    C1512346 (UMLS CUI [1])
    C0589121 (UMLS CUI [2,1])
    C1524062 (UMLS CUI [2,2])
    C1706712 (UMLS CUI [3])
    C0045212 (UMLS CUI [4])
    C1262160 (UMLS CUI [5])
    Item Group
    C0680251 (UMLS CUI)
    Hbv DNA Test Negative
    Item
    1. hbv dna negative (< 4,700 copies/ml) consistently at the last 2 visit (at least 2 consecutive visits, at one month interval)
    boolean
    C1256114 (UMLS CUI [1,1])
    C1513916 (UMLS CUI [1,2])
    Antiviral Therapy | Biological Response Modifier Therapy | Steroid therapy
    Item
    2. patient is currently receiving antiviral immunomodulatory or corticosteroid therapy.
    boolean
    C0280274 (UMLS CUI [1])
    C0005527 (UMLS CUI [2])
    C0149783 (UMLS CUI [3])
    Lamivudine | lobucavir | adefovir | Nucleoside Investigational | Therapeutic procedure Hepatitis B | Clevudine Clinical Trial Therapeutic procedure Ended
    Item
    3. patients previously treated with lamivudine, lobucavir, adefovir or any other investigational nucleoside for hbv infection after cessation of treatment in l-fmau-201 study.
    boolean
    C0209738 (UMLS CUI [1])
    C0286536 (UMLS CUI [2])
    C0050175 (UMLS CUI [3])
    C0028621 (UMLS CUI [4,1])
    C1517586 (UMLS CUI [4,2])
    C0087111 (UMLS CUI [5,1])
    C0019163 (UMLS CUI [5,2])
    C0045212 (UMLS CUI [6,1])
    C0008976 (UMLS CUI [6,2])
    C0087111 (UMLS CUI [6,3])
    C1272693 (UMLS CUI [6,4])
    Ascites | Bleeding varices | Hepatic Encephalopathy
    Item
    4. patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy.
    boolean
    C0003962 (UMLS CUI [1])
    C0333106 (UMLS CUI [2])
    C0019151 (UMLS CUI [3])
    HCV coinfection | Coinfection HDV | HIV coinfection
    Item
    5. patient is coinfected with hcv, hdv or hiv.
    boolean
    C1698259 (UMLS CUI [1])
    C0275524 (UMLS CUI [2,1])
    C0011220 (UMLS CUI [2,2])
    C4062778 (UMLS CUI [3])
    Liver Cirrhosis Evidence Clinical | Liver carcinoma Evidence Clinical | Alpha fetoprotein measurement | Sonography
    Item
    6. patient with clinical evidence of cirrhosis or hepatocellular carcinoma (®-fetoprotein) evaluation will be based on alpha-fetoprotein primarily. if alpha-fetoprotein level is suggestive of cirrhosis or hepatocellular carcinoma, confirmation will be made with sonography etc.
    boolean
    C0023890 (UMLS CUI [1,1])
    C3887511 (UMLS CUI [1,2])
    C0205210 (UMLS CUI [1,3])
    C2239176 (UMLS CUI [2,1])
    C3887511 (UMLS CUI [2,2])
    C0205210 (UMLS CUI [2,3])
    C0201539 (UMLS CUI [3])
    C0041618 (UMLS CUI [4])
    Pregnancy | Breast Feeding
    Item
    7. patient is pregnant or breast-feeding.
    boolean
    C0032961 (UMLS CUI [1])
    C0006147 (UMLS CUI [2])
    Contraceptive methods Unwilling | Condoms, Male | Female Sterilization | Hysterectomy | Bilateral tubal ligation | Postmenopausal state | Contraception, Barrier | Intrauterine Devices | Vaginal Spermicides | Sexual Abstinence
    Item
    8. patient is unwilling to use an “effective” method of contraception during the study and for up to 3 months after the use of study drug ceases. for males, condoms should be used. females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal or using at least a medically acceptable barrier method of contraception (i.e., iud, barrier methods with spermicide or abstinence)
    boolean
    C0700589 (UMLS CUI [1,1])
    C0558080 (UMLS CUI [1,2])
    C0009653 (UMLS CUI [2])
    C0015787 (UMLS CUI [3])
    C0020699 (UMLS CUI [4])
    C0589114 (UMLS CUI [5])
    C0232970 (UMLS CUI [6])
    C0004764 (UMLS CUI [7])
    C0021900 (UMLS CUI [8])
    C0087145 (UMLS CUI [9])
    C0036899 (UMLS CUI [10])
    Substance Use Disorders Relevant Clinical
    Item
    9. patient has a clinically relevant history of abuse of alcohol or drugs.
    boolean
    C0038586 (UMLS CUI [1,1])
    C2347946 (UMLS CUI [1,2])
    C0205210 (UMLS CUI [1,3])
    Gastrointestinal Diseases Significant | Kidney Diseases | Decompensated liver disease | Bronchopulmonary disease | nervous system disorder | Cardiovascular Diseases | Malignant Neoplasms | Hypersensitivity
    Item
    10. patient has a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease.
    boolean
    C0017178 (UMLS CUI [1,1])
    C0750502 (UMLS CUI [1,2])
    C0022658 (UMLS CUI [2])
    C4075847 (UMLS CUI [3])
    C1096000 (UMLS CUI [4])
    C0027765 (UMLS CUI [5])
    C0007222 (UMLS CUI [6])
    C0006826 (UMLS CUI [7])
    C0020517 (UMLS CUI [8])
    Estimation of creatinine clearance by Cockcroft-Gault formula
    Item
    11. patient has creatinine clearance less than 60ml/min as estimated by the following formula:
    boolean
    C2711451 (UMLS CUI [1])
    Age | Body Weight | Creatinine measurement, serum | Gender
    Item
    (140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dl]) [note: multiply estimates by 0.85 for women]
    boolean
    C0001779 (UMLS CUI [1])
    C0005910 (UMLS CUI [2])
    C0201976 (UMLS CUI [3])
    C0079399 (UMLS CUI [4])
    Retour au début de la page 

    Aide

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial